| Schedule of reporting segment |
| | | | | | | | | | Three months ended September 30, 2026 | | | NeuroStar | | | Greenbrook | | | Total | Revenues | | $ | 15,770 | | $ | 26,192 | | $ | 41,962 | Cost of revenues | | | 3,610 | | | 16,462 | | | 20,072 | Segment gross profit | | $ | 12,160 | | $ | 9,730 | | $ | 21,890 | | | | | | | | | | | Significant Segment Expense | | | | | | | | | | Selling, General and Administrative | | | | | | | | | | Direct | | $ | 6,217 | | $ | 6,559 | | $ | 12,776 | | | | | | | | | | | Research and development | | | | | | | | | | Direct | | | 1,132 | | | 58 | | | 1,190 | | | | | | | | | | | Segment profit | | $ | 4,811 | | $ | 3,113 | | $ | 7,924 | | | | | | | | | | | Unallocated expenses | | | | | | | | | | General and Administrative | | | | | | | | $ | 7,383 | Other income, net | | | | | | | | | (47) | Interest expense | | | | | | | | | 2,144 | | | | | | | | | | | Net loss | | | | | | | | $ | (1,556) | | | | | | | | | | |
| | | | | | | | | | Three months ended September 30, 2025 | | | NeuroStar | | | Greenbrook | | | Total | Revenues | | $ | 15,489 | | $ | 21,808 | | $ | 37,297 | Cost of revenues | | | 4,607 | | | 15,582 | | | 20,189 | Segment gross profit | | $ | 10,882 | | $ | 6,226 | | $ | 17,108 | | | | | | | | | | | Significant Segment Expense | | | | | | | | | | Selling, General and Administrative | | | | | | | | | | Direct | | $ | 9,136 | | $ | 7,148 | | $ | 16,284 | | | | | | | | | | | Research and development | | | | | | | | | | Direct | | | 1,452 | | | 52 | | | 1,504 | | | | | | | | | | | Segment profit/(loss) | | $ | 294 | | $ | (974) | | $ | (680) | | | | | | | | | | | Unallocated expenses | | | | | | | | | | General and Administrative | | | | | | | | $ | 6,641 | Other income, net | | | | | | | | | (126) | Interest expense | | | | | | | | | 2,206 | | | | | | | | | | | Net loss | | | | | | | | $ | (9,401) | | | | | | | | | | |
| | | | | | | | | | Nine months ended September 30, 2026 | | | NeuroStar | | | Greenbrook | | | Total | Revenues | | $ | 43,372 | | $ | 74,612 | | $ | 117,984 | Cost of revenues | | | 9,780 | | | 48,937 | | | 58,717 | Segment gross profit | | $ | 33,592 | | $ | 25,675 | | $ | 59,267 | | | | | | | | | | | Significant Segment Expense | | | | | | | | | | Selling, General and Administrative | | | | | | | | | | Direct | | $ | 20,623 | | $ | 22,022 | | $ | 42,645 | | | | | | | | | | | Research and development | | | | | | | | | | Direct | | | 3,685 | | | 205 | | | 3,890 | | | | | | | | | | | Segment profit | | $ | 9,284 | | $ | 3,448 | | $ | 12,732 | | | | | | | | | | | Unallocated expenses | | | | | | | | | | General and Administrative | | | | | | | | $ | 22,687 | Other income, net | | | | | | | | | (1,229) | Loss on extinguishment of debt | | | | | | | | | 539 | Interest expense | | | | | | | | | 6,535 | | | | | | | | | | | Net loss | | | | | | | | $ | (15,800) |
| | | | | | | | | | Nine months ended September 30, 2025 | | | NeuroStar | | | Greenbrook | | | Total | Revenues | | $ | 43,889 | | $ | 63,491 | | $ | 107,380 | Cost of revenues | | | 12,068 | | | 44,708 | | | 56,776 | Segment gross profit | | $ | 31,821 | | $ | 18,783 | | $ | 50,604 | | | | | | | | | | | Significant Segment Expense | | | | | | | | | | Selling, General and Administrative | | | | | | | | | | Direct | | $ | 26,761 | | $ | 22,414 | | $ | 49,175 | | | | | | | | | | | Research and development | | | | | | | | | | Direct | | | 4,756 | | | 162 | | | 4,918 | | | | | | | | | | | Segment profit/(loss) | | $ | 304 | | $ | (3,793) | | $ | (3,489) | | | | | | | | | | | Unallocated expenses | | | | | | | | | | General and Administrative | | | | | | | | $ | 22,904 | Other income, net | | | | | | | | | (561) | Interest expense | | | | | | | | | 6,097 | | | | | | | | | | | Net loss | | | | | | | | $ | (31,929) |
|